Carmine Therapeutics

Biotechnology ResearchMassachusetts, United States2-10 Employees

Carmine Therapeutics is a Cambridge, Massachusetts-based biotechnology company developing a new class of non-viral gene therapies. It utilizes red blood cell–derived extracellular vesicles as delivery vehicles for proprietary payloads, aiming to enable genetic interventions without viral vectors. Founded in 2019 with backing from EVX Ventures and academic founders, the company benefits from the guidance of Harvey Lodish, who chairs its Scientific Advisory Board.

Operating in the biotechnology research industry, Carmine Therapeutics targets rare disease applications with a delivery platform designed for non-viral gene therapy. A notable milestone is its 2020 research alliance with Takeda Pharmaceuticals to pursue non-viral gene therapies for two targets. The company has been recognized in the biotech community, including a listing among FierceBiotech's Fierce 15 in 2020.

Sign up for free to view info

Email Format Employee directory